Abstract: A therapeutic supramolecule including a first component having a binding effector molecule such as a protein, a polypeptide, a lipid, or a sugar; and a second component including a therapeutic effector molecule such as a protein, a polypeptide, a lipid, or a sugar, where the binding effector molecule and therapeutic effector molecule are linked by a joining molecule, a peptide, or a dendrimer.

Abstract: A supramolecule has a first supramolecular component including a first effector molecule covalently joined to a first nucleic acid, and a second supramolecular component including a second effector molecule covalently joined to a second nucleic acid, wherein the second nucleic acid has a region of at least partial complementarity to the first nucleic acid, wherein the first nucleic acid is in a base pairing relationship with the second nucleic acid and the first or second effector molecules are proteins, polypeptides, lipids or sugars. The supramolecule may further have a third supramolecule component which includes a third effector molecule covalently joined to a third nucleic acid, wherein the third nucleic acid has a region of at least partial complementary to the first nucleic acid or the second nucleic acid and wherein the third nucleic acid is in a base pairing relationship with the second nucleic acid or the first nucleic acid.

Abstract: A supramolecule has a first supramolecular component including a first effector molecule covalently joined to a first nucleic acid, and a second supramolecular component including a second effector molecule covalently joined to a second nucleic acid, wherein the second nucleic acid has a region of at least partial complementarity to the first nucleic acid, wherein the first nucleic acid is in a base pairing relationship with the second nucleic acid and the first or second effector molecules are proteins, polypeptides, lipids or sugars. The supramolecule may further have a third supramolecule component which includes a third effector molecule covalently joined to a third nucleic acid, wherein the third nucleic acid has a region of at least partial complementary to the first nucleic acid or the second nucleic acid and wherein the third nucleic acid is in a base pairing relationship with the second nucleic acid or the first nucleic acid.

Abstract: Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. One effector molecule is a binding molecule such as an antibody or Fc receptor that binds to a molecular target such as a virus or antibody at a site of infection or tumor, and another effector molecule is a therapeutic molecule such as an enzyme or drug. The joining component may be a liposome, protein or an organic polymer (including a dendrimer type polymer), and may be of sufficient length and/or flexibility to permit the therapeutic molecule to physically interact with the target at the same time as the binding molecule. Supramolecules are formed containing at least two supramolecular component molecules that contain an effector molecule and a nucleic acid chain.

Abstract: Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. One effector molecule is a binding molecule such as an antibody or Fc receptor that binds to a molecular target such as a virus or antibody at a site of infection or tumor, and another effector molecule is a therapeutic molecule such as an enzyme or drug. The joining component may be a liposome, protein or an organic polymer (including a dendrimer type polymer), and may be of sufficient length and/or flexibility to permit the therapeutic molecule to physically interact with the target at the same time as the binding molecule. Supramolecules are formed containing at least two supramolecular component molecules that contain an effector molecule and a nucleic acid chain.

Abstract: Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. At least one of the effector molecules can bind to a target molecule and at least one of the other effector molecules has therapeutic properties. The joining component can be liposomes, proteins and organic polymers including dendrimer polymers, and can be of sufficient length and/or flexibility to permit the therapeutic effector molecule to interact with a target at the same time as the binding molecules. An antiviral liposome is prepared by coupling to a liposome outer surface a hydrolytic enzyme capable of digesting a viral component and a target-binding moiety which may be a polypeptide, glycoprotein or glycoprotein fragment having specificity for viruses such as HIV-1, influenza virus and hepatitis virus. The hydrolytic enzyme may be a glycosidase, phospholipase, lipase, cholesterol esterase, nuclease or protease.